Novo Nordisk shares rose Wednesday after ... formulations so their bodies can get used to the drug. At times, Novo has ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The drug has also been evaluated in adults and adolescents. Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025. Haemophilia A is a rare blood disorder ...

Novo Nordisk shares rose ... their bodies can get used to the drug. At times, Novo has limited the amount of starter doses it shipped because it struggled to make enough of the drug and wanted ...